TransMedics Group, Inc. — Director's Dealing 2023

Sep 5, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TransMedics Group, Inc. (TMDX)
CIK: 0001756262
Period of Report: 2023-08-31

Reporting Person: Provost Miriam (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-08-31	Common Stock	M	1785	$3.22	Acquired	22624	Direct
2023-08-31	Common Stock	M	3695	$38.46	Acquired	26319	Direct
2023-08-31	Common Stock	S	2708	$66.52	Disposed	23611	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-08-31	Stock Option (Right to Buy)	$3.22	M	1785	Disposed	2028-04-05	Common Stock (1785)	Direct
2023-08-31	Stock Option (Right to Buy)	$38.46	M	3695	Disposed	2031-02-24	Common Stock (3695)	Direct

Footnotes

F1: The exercise followed the sell-to-cover process, whereby a portion of the shares acquired through the exercise were sold in the open market, with the proceeds used to fund the aggregate exercise price of the options.

F2: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $66.40 to $66.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3: Includes 5,685 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F4: The option is fully vested.

F5: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 24, 2021.